Search database
LIST OPTIONS
Filter
21
Filtered Results: 21
Text search: Drugs for Neglected Diseases Intiative DNDi
Featured
Language
Document type
Studies & Reports
8
Strategic & Response Plan
3
No document type
3
Guidelines
2
Videos
2
Manuals
1
Resource Platforms
1
Fact sheets
1
Countries / Regions
Global
3
Latin America and the Carribbean
3
Colombia
2
Kenya
1
Africa
1
Ethiopia
1
Authors & Publishers
Drugs for Neglected Diseases initiative DNDi
4
DNDi - Drugs for neglected diseases initiative
3
Forsyth, C.
3
World Health Organization WHO
2
Avaria, A. et al.
1
Bernal, O.
1
Brot für die Welt
1
DNDi Latin America
1
et al.
1
Federal Ministry of Health, Ethiopia
1
Khan, J.
1
L.R. Cruz
1
LEAP
1
M.C. Mollo, et al.
1
Marchiol, A
1
McGloin, J.
1
Médecins Sans Frontières
1
MSF Access Campaign
1
N.I. Agudelo Higuita, S.A. Hamer, et al.
1
Oliveira, R.G. de.
1
Pan American Health Organization PAHO
1
Sanmatino, M.
1
Unitaid
1
Wamai, R.
1
World Health Organisation (WHO)
1
Ziaggi, G.
1
Publication Years
Category
Countries
6
Clinical Guidelines
3
Pharmacy & Technologies
2
Toolboxes
NTDs
15
Pharmacy
2
HIV
1
Global Health Education
1
DNDi’s long-term goal for sleeping sickness, also known as human African trypanosomiasis (HAT), is to develop and register two new drugs that are effective against both Stage 1 and Stage 2 of the disease and both subspecies of the parasite, T.b. gambiense and T.b. rhodesiense. T.b. rhodesiense is ... more
1 billion people are at risk of infection with leishmaniasis, a neglected disease strongly linked to poverty. There’s no single, simple cure: current treatments are complex and need to be adapted to the form of the disease and geographical region.
Leishmaniasis is among the most neglected diseases. The most common form is cutaneous leishmaniasis that forms lesions on the skin. The only treatment available for cutaneous leishmaniasis is highly toxic. In some cases, patients have died because of the treatment, even though cutaneous leishmania... more
Accessed on 04.04.2023 The Drugs for Neglected Diseases initiative (DNDi) is an international non-profit organization that discovers, develops, and delivers safe, effective, and affordable treatments for the most neglected patients
La Iniciativa Medicamentos para Enfermedades Olvidadas (DNDi) es una organización internacional sin fines de lucro que proporciona tratamientos seguros, eficaces y asequibles para los pacientes más desatendidos, desde el laboratorio hasta su llegada a las manos de las poblaciones más vulnerables ... more
A Iniciativa Medicamentos para Doenças Negligenciadas (DNDi) é uma organização internacional sem fins lucrativos que disponibiliza medicamentos seguros, eficazes e acessíveis para doenças negligenciadas, desde o laboratório até sua chegada às mãos das populações mais vulneráveis do mund... more
La leishmaniasis es una enfermedad tropical desatendida sensible al clima, trasmitida por la picadura de insectos flebótomos y se calcula que amenaza a mil millones de personas en todo el mundo. Esta enfermedad altamente compleja se presenta de varias formas clínicas, causadas por 20 especies ... more
Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 117: e200460, 2022 Integrating the multiple dimensions of the problem into a coherent approach adapted to field realities and needs represents an immense challenge, but the payoff is more effective and sustainable experiences, with higher social awareness... more
Rev. Panam Salud Publica. 2017;41:e153. doi: 10.26633/RPSP.2017.153 Worldwide, over 6 million people are infected with Trypanosoma cruzi, the pathogen that causes Chagas disease (CD). In the Americas, CD creates the greatest burden in disability-adjusted life years of any parasitic infection. In Co... more
A Mini Review of Antiparasitic Agents explored between 2010-2021. Frontiers in Chemistry 9:771143
The World Health Organization (WHO) and the global community of countries, partners, donors, technical experts, scientists and field implementation teams continue to work towards the ultimate goal of a world free of the burden of neglected tropical diseases (NTDs).
This document focuses on making recommendations for the diagnosis and treatment of Chagas disease, an infection caused by Trypanosoma cruzi, the protozoan agent of a systemic parasitic disease. Methodology: These clinical practice guidelines were prepared following the WHO handbook for guideline dev... more
Over 6 million people worldwide are infected with Trypanosoma cruzi, the protozoan that causes Chagas disease. Endemic in 21 Latin American countries, the disease can be transmitted by vector insects called triatomines — also known as “kissing bugs” —, foods or beverages contaminated with th... more
J Glob Health Sci. 2020 Jun;2(1):e3. A group of enzootic and zoonotic protozoan infections, the leishmaniases constitute among the most severely neglected tropical diseases (NTDs) and are found in all continents except Oceania. Representing the most common infectious diseases, NTDs comprise an open-... more
This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of the opportunities for – and threats to – expand... more
Drug registration in Kenya started in 1982; the process mainly involves an evaluation committee at the Kenya Pharmacy and Poisons Board (PPB) that aims to approve products based on quality, safety and efficacy.
Technology landscape
The Lancet Microbe Series Chagas Disease 2 Volume 5, Issue 10100946 October 2024
The growing challenges for people in low and middle-income countries to access new medicines. Analysis 58